Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, September 2008, p. 3444-3446, Vol. 52, No. 9
0066-4804/08/$08.00+0 doi:10.1128/AAC.00629-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain,1 CIBER de Enfermedades Respiratorias (CIBER RES CD06/06/0058), Palma de Mallorca, Spain2
Received 14 May 2008/ Returned for modification 3 June 2008/ Accepted 28 June 2008
We studied the activity of voriconazole against 400 clinical strains of Aspergillus from the pre-voriconazole (1999 to 2002) and post-voriconazole (2003 to 2007) periods. Although the mean MICs of strains from the post-voriconazole period were slightly higher (0.39 versus 0.57 µg/ml; P < 0.001), all strains were susceptible to voriconazole and presented an MIC of
2 µg/ml.
Published ahead of print on 7 July 2008.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»